Currently, there are no studies available that help assess the individual benefits of EBRT versus RP based on patient characteristics [9,10,11], even though it has been suggested that parameters such as age, BMI, tumor grade, and pretreatment prostate-specific antigen (PSA) levels do influence both recurrence-free survival and toxicity [12]. The gene discussed is KLK3; the disease is neoplasm.